Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE: Safety and Efficacy of Insuget in Type 2 Diabetes
NCT05161741Phase 4Completed
- Sponsor
- Getz Pharma
- Start
- Jan 2021
- Primary completion
- Nov 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of human insulin in type 2 diabetes mellitus (T2DM), sponsored by Getz Pharma. Primary endpoints: Frequency of adverse events at 6 months and Frequency of serious adverse events at 6 months. Started Jan 2021; status: completed.
02
Drugs
human insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05161741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161741.